| 16.54 1.29 (8.46%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.34 |
1-year : | 22.59 |
| Resists | First : | 16.55 |
Second : | 19.34 |
| Pivot price | 15.01 |
|||
| Supports | First : | 14.67 |
Second : | 13.51 |
| MAs | MA(5) : | 15.2 |
MA(20) : | 14.88 |
| MA(100) : | 16.23  |
MA(250) : | 21.19 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 75.8 |
D(3) : | 63.3 |
| RSI | RSI(14): 64 |
|||
| 52-week | High : | 31.7 | Low : | 12.68 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RDUS ] has closed Bollinger Bands are 29.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.58 - 16.64 | 16.64 - 16.69 |
| Low: | 15.29 - 15.37 | 15.37 - 15.42 |
| Close: | 16.42 - 16.54 | 16.54 - 16.64 |
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
Mon, 08 Apr 2024
Radius Health, Inc. (NASDAQ:RDUS) Q2 2024 Earnings Call Transcript - Yahoo Finance
Sat, 06 Jan 2024
Radius Health, Inc. (NASDAQ:RDUS) Q1 2024 Earnings Call Transcript - Yahoo Finance
Mon, 15 Aug 2022
This Top Insider is Bulking up on Radius Health Stock - TipRanks
Mon, 15 Aug 2022
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc. - GlobeNewswire
Thu, 23 Jun 2022
Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 28 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 6.3 (%) |
| Held by Institutions | 86.5 (%) |
| Shares Short | 634 (K) |
| Shares Short P.Month | 729 (K) |
| EPS | -9.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.94 |
| Profit Margin | -10.3 % |
| Operating Margin | -3.5 % |
| Return on Assets (ttm) | -3 % |
| Return on Equity (ttm) | -34.9 % |
| Qtrly Rev. Growth | -16.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 96.62 |
| EBITDA (p.s.) | 0.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 78 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -1.7 |
| PEG Ratio | -0.6 |
| Price to Book value | 0.72 |
| Price to Sales | 0.17 |
| Price to Cash Flow | 5.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|